# Donald A. Berry

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/donald-a-berry/

## Facts

| Field | Value |
| --- | --- |
| Citations | 61,920 |
| Field | Breast Cancer Treatment Studies |
| h-index | 110 |
| i10-index | 346 |
| Last Known Institution | Berry & Associates (United States) |
| OpenAlex ID | https://openalex.org/A5073571977 |
| ORCID iD | https://orcid.org/0000-0002-7657-3871 |
| Works | 682 |

## Researcher papers

Showing 12 of 22.

- [Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741](https://scholariq.org/papers/randomized-trial-of-dose-dense-versus-conventionally-scheduled-and-sequential/)
- [Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343](https://scholariq.org/papers/lumpectomy-plus-tamoxifen-with-or-without-irradiation-in-women-age-70-years-or/)
- [Revision of the American Joint Committee on Cancer Staging System for Breast Cancer](https://scholariq.org/papers/revision-of-the-american-joint-committee-on-cancer-staging-system-for-breast/)
- [Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer](https://scholariq.org/papers/lumpectomy-plus-tamoxifen-with-or-without-irradiation-in-women-70-years-of-age/)
- [Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)](https://scholariq.org/papers/impact-of-the-addition-of-carboplatin-and-or-bevacizumab-to-neoadjuvant-once-per/)
- [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/)
- [Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-veliparib-carboplatin-treatment-in-breast-cancer/)
- [Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative](https://scholariq.org/papers/personalized-medicine-in-a-phase-i-clinical-trials-program-the-md-anderson/)
- [BRCAPRO Validation, Sensitivity of Genetic Testing of <i>BRCA1/BRCA2</i>, and Prevalence of Other Breast Cancer Susceptibility Genes](https://scholariq.org/papers/brcapro-validation-sensitivity-of-genetic-testing-of-i-brca1-brca2-i-and/)
- [Addressing overdiagnosis and overtreatment in cancer: a prescription for change](https://scholariq.org/papers/addressing-overdiagnosis-and-overtreatment-in-cancer-a-prescription-for-change/)
- [Adaptive Randomization of Neratinib in Early Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-neratinib-in-early-breast-cancer/)
- [Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib](https://scholariq.org/papers/molecular-heterogeneity-and-response-to-neoadjuvant-human-epidermal-growth/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Statistical Methods in Clinical Trials](https://scholariq.org/topics/statistical-methods-in-clinical-trials/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Berry & Associates (United States)](https://scholariq.org/institutions/berry-and-associates-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.